165 related articles for article (PubMed ID: 23029544)
1. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Kwei KA; Baker JB; Pelham RJ
PLoS One; 2012; 7(9):e46518. PubMed ID: 23029544
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
3. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
O'Brien C; Wallin JJ; Sampath D; GuhaThakurta D; Savage H; Punnoose EA; Guan J; Berry L; Prior WW; Amler LC; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2010 Jul; 16(14):3670-83. PubMed ID: 20453058
[TBL] [Abstract][Full Text] [Related]
4. Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
de Lint K; Poell JB; Soueidan H; Jastrzebski K; Vidal Rodriguez J; Lieftink C; Wessels LF; Beijersbergen RL
Mol Cancer Ther; 2016 Jul; 15(7):1545-56. PubMed ID: 27196766
[TBL] [Abstract][Full Text] [Related]
5. [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
Cawthorne C; Burrows N; Gieling RG; Morrow CJ; Forster D; Gregory J; Radigois M; Smigova A; Babur M; Simpson K; Hodgkinson C; Brown G; McMahon A; Dive C; Hiscock D; Wilson I; Williams KJ
Mol Cancer Ther; 2013 May; 12(5):819-28. PubMed ID: 23427298
[TBL] [Abstract][Full Text] [Related]
6. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition.
Kirkpatrick DS; Bustos DJ; Dogan T; Chan J; Phu L; Young A; Friedman LS; Belvin M; Song Q; Bakalarski CE; Hoeflich KP
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19426-31. PubMed ID: 24218548
[TBL] [Abstract][Full Text] [Related]
8. Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.
Usman MW; Gao J; Zheng T; Rui C; Li T; Bian X; Cheng H; Liu P; Luo F
Cell Death Dis; 2018 Jul; 9(8):809. PubMed ID: 30042442
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
10. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.
Soler A; Figueiredo AM; Castel P; Martin L; Monelli E; Angulo-Urarte A; Milà-Guasch M; Viñals F; Baselga J; Casanovas O; Graupera M
Clin Cancer Res; 2016 Dec; 22(23):5805-5817. PubMed ID: 27225693
[TBL] [Abstract][Full Text] [Related]
12. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.
Burrows N; Babur M; Resch J; Ridsdale S; Mejin M; Rowling EJ; Brabant G; Williams KJ
J Clin Endocrinol Metab; 2011 Dec; 96(12):E1934-43. PubMed ID: 21994956
[TBL] [Abstract][Full Text] [Related]
13. Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells.
Shi L; Gao X; Li X; Jiang N; Luo F; Gu C; Chen M; Cheng H; Liu P
Curr Mol Med; 2015; 15(5):478-86. PubMed ID: 25941816
[TBL] [Abstract][Full Text] [Related]
14. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
15. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
Reikvam H; Tamburini J; Skrede S; Holdhus R; Poulain L; Ersvaer E; Hatfield KJ; Bruserud Ø
Br J Haematol; 2014 Jan; 164(2):200-11. PubMed ID: 24383842
[TBL] [Abstract][Full Text] [Related]
16. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
17. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
18. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Chakrabarty A; Sánchez V; Kuba MG; Rinehart C; Arteaga CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2718-23. PubMed ID: 21368164
[TBL] [Abstract][Full Text] [Related]
19. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
[TBL] [Abstract][Full Text] [Related]
20. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
